Department of Anaesthesiology and Intensive Care Medicine, University College Cork, Cork, Ireland.
Global Market Access, Pharmacosmos A/S, Holbaek, Denmark.
Adv Ther. 2020 Mar;37(3):1218-1232. doi: 10.1007/s12325-020-01241-0. Epub 2020 Feb 6.
Intravenous (IV) iron is typically the preferred treatment for patients with iron deficiency anemia (IDA) who cannot tolerate or absorb oral iron, or who require fast replenishment of iron stores pre-operatively. Several IV iron formulations are available with different dosing characteristics affecting infusion speed and maximum dose. The aim was to develop a resource impact model to calculate the cost of establishing an IV iron clinic and model resource impact of different IV irons to inform clinicians and service providers implementing innovative pre-operative IV iron services in Ireland.
A resource impact tool was developed to model resource utilization and IDA treatment costs. Two fast-administration, high-dose formulations of IV iron are available in Ireland: iron isomaltoside 1000/ferric derisomaltose (IIM) and ferric carboxymaltose (FCM). The tool modeled clinic throughput based on their different dosing characteristics in a specific IDA population, capturing fixed overheads, variable costs, clinic income from private and publicly-funded patients, and savings associated with IV iron.
Based on a 70:30 split between public and private patients in a new pre-operative service with capacity for 12 infusion slots weekly, IIM would facilitate correction of iron deficits in 474 patients annually, resulting in a net annual clinic balance of €42,736 on income of €159,887 and net costs of €117,151. FCM would facilitate treatment of 353 patients, resulting in a net annual clinic balance of €36,327 on income of €116,050 and costs of €79,722, a difference of €6408 and 121 patients treated in favor of using IIM over FCM.
Based on this provider-perspective analysis, IIM would maximize clinic throughput relative to other IV iron formulations, allowing clinicians in Ireland to optimize their current service provision and expenditure, and model the impact of introducing IV iron clinics for pre-operative patients with IDA.
静脉(IV)铁通常是不能耐受或吸收口服铁或需要术前快速补充铁储存的缺铁性贫血(IDA)患者的首选治疗方法。有几种不同的 IV 铁制剂,其剂量特征会影响输注速度和最大剂量。目的是开发一种资源影响模型,以计算建立 IV 铁诊所的成本,并对不同 IV 铁的资源影响进行建模,以为在爱尔兰实施创新的术前 IV 铁服务的临床医生和服务提供者提供信息。
开发了一种资源影响工具,用于对资源利用和 IDA 治疗成本进行建模。在爱尔兰,有两种快速给药、高剂量的 IV 铁制剂:异麦芽糖酐 1000/铁去异麦芽糖铁(IIM)和羧基麦芽糖铁(FCM)。该工具根据特定 IDA 人群中不同的剂量特征对诊所吞吐量进行建模,同时捕获固定间接费用、可变成本、私人和公共资助患者的诊所收入,以及与 IV 铁相关的节省。
基于新术前服务中公私患者比例为 70:30,且每周有 12 个输液位,IIM 每年将使 474 名患者的缺铁得到纠正,年收入为 159887 欧元,净成本为 117151 欧元,诊所将有 474 名患者缺铁得到纠正,每年可获得净收入 159887 欧元,净成本为 117151 欧元。FCM 将治疗 353 名患者,年收入为 116050 欧元,成本为 79722 欧元,诊所净收入为 36327 欧元,与使用 FCM 相比,使用 IIM 的差异为 6408 欧元和 121 名患者。
基于该提供者角度的分析,与其他 IV 铁制剂相比,IIM 将使诊所的吞吐量最大化,使爱尔兰的临床医生能够优化其当前的服务提供和支出,并为术前 IDA 患者引入 IV 铁诊所的影响建模。